News & Updates

Elacestrant, a novel oral selective oestrogen receptor (ER) degrader, significantly improves progression-free survival (PFS) vs standard-of-care (SoC) endocrine therapy (ET) in patients with ER-positive, HER2-negative advanced breast cancer whose disease progressed after 1–2 prior lines of ET and a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, results of the phase III EMERALD trial have shown.

Use of statins results in reduced all-cause mortality in nearly 30,000 veterans with colorectal cancer (CRC), results of a study have shown.

The use of hormonal replacement therapy (HRT) among postmenopausal women may be associated with a reduced risk of mortality after a COVID-19 diagnosis, according to a retrospective study from Sweden.

A team of Singapore-based researchers has identified two blood biomarkers that not only predict clinical response to immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) patients but also the incidence of side effects from the same treatment.

Patients who take multivitamin supplements at a moderate dose following their diagnosis of nonmetastatic colorectal cancer (CRC) appear to have a lower mortality, reports a recent study.

Prostate cancer (PCa) patients with higher lymph node (LN) risk scores and Gleason grade who are treated with whole pelvis radiotherapy (WPRT) have better overall survival (OS), reports a study.